Journal of Clinical Epidemiology
Volume 59, Issue 8 , Pages 808-818 , August 2006

Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations

  • Jason M. Glanz

      Affiliations

    • Clinical Research Unit, Kaiser Permanente, P. O. Box 378006, Colorado, Denver, CO, 80237-8066, USA
    • Corresponding Author InformationCorresponding author. Tel.: 303-636-3118; fax: 303-636-3109.
    • ,
  • David L. McClure

      Affiliations

    • Clinical Research Unit, Kaiser Permanente, P. O. Box 378006, Colorado, Denver, CO, 80237-8066, USA
    • ,
  • Stanley Xu

      Affiliations

    • Clinical Research Unit, Kaiser Permanente, P. O. Box 378006, Colorado, Denver, CO, 80237-8066, USA
    • ,
  • Simon J. Hambidge

      Affiliations

    • Clinical Research Unit, Kaiser Permanente, P. O. Box 378006, Colorado, Denver, CO, 80237-8066, USA
    • Community Health Services, Denver Health Medical Center, Denver, CO, USA
    • Department of Pediatrics, University of Colorado School of Medicine, Denver, CO, USA
    • ,
  • Martin Lee

      Affiliations

    • UCLA Center for Vaccine Research, Torrance, CA, USA
    • ,
  • Margarette S. Kolczak

      Affiliations

    • Centers for Disease Control and Prevention, Atlanta, GA, USA
    • ,
  • Ken Kleinman

      Affiliations

    • Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA, USA
    • ,
  • John P. Mullooly

      Affiliations

    • Center for Health Research, Northwest Kaiser Permanente, Portland, OR, USA
    • ,
  • Eric K. France

      Affiliations

    • Clinical Research Unit, Kaiser Permanente, P. O. Box 378006, Colorado, Denver, CO, 80237-8066, USA

,Accepted 16 November 2005.

References 

  1. Black C, Kaye J, Jick H. MMR vaccine and idiopathic thrombocytopenic purpura. J Clin Pharmacol. 2003;55:107–111
  2. Miller E, Waight P, Farrington CP, et al. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child. 2001;84(3):227–229
  3. Szklo M, Nieto M. Basic study designs in analytical epidemiology. In:  Szklo M,  Nieto M editor. Epidemiology: Beyond the basics. Gaithersburg, MD: Aspen Publishers, Inc; 2000;p. 3–52
  4. Rothman K, Greenland S. In:  Rothman K,  Greenland S editor. Modern epidemiology. 2nd ed.. Philadelphia, PA: Lippincott-Raven Publishers; 1998;p. 79–91
  5. Fine PE, Chen RT. Confounding in studies of adverse reactions to vaccines. Am J Epidemiol. 1992;136(2):121–135
  6. Destefano F, Mullooly JP, Okoro CA, et al. Childhood vaccinations, vaccination timing, and the risk of type I diabetes mellitus. Pediatrics. 2001;108(6):112–117
  7. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med. 2001;344(8):564–572
  8. Black S, Shinefield H, Ray P, et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) project. Pediatr Infect Dis J. 1997;16(5):500–503
  9. Mullooly JP, Pearson J, Drew L, et al. Wheezing lower respiratory disease and vaccination of full-term infants. Pharmacoepidemiol Drug Saf. 2002;11:21–30
  10. Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of bell's palsy in Switzerland. N Engl J Med. 2004;350(9):896–903
  11. Farrington PC, Miller E, Taylor B. MMR and autism: further evidence against a causal association. Vaccine. 2001;19:3632–3635
  12. Kramarz P, DeStefano F, Gargiullo P, et al. Does influenza exacerbate asthma? Analysis of a large cohort of children with asthma. Arch Fam Med. 2000;9(7):617–623
  13. Chen RT. Safety of vaccines. In:  Plotkin SA,  Orenstein WA editor. Vaccines. 3rd ed.. Philadelphia, PA: W.B. Saunders Company; 1999;p. 1144–1163
  14. Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am. J Epidemiol. 1996;143:1165–1173
  15. Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics. 1995;51:228–235
  16. Andrew NJ. Statistical assessment of the association between vaccination and rare events post-licensure. Vaccine. 2002;20:S49–S53
  17. Farrington CP. Control without separate methods: evaluation of vaccine safety using case-only methods. Vaccine. 2004;22(15–16):2064–2070
  18. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: The self-controlled case series method. Stat Med. 2006;[Epub ahead of print]
  19. Chen RT, Glasser JW, Rhodes PH, et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics. 1997;99:765–773
  20. Chu YW, Korb J, Sakamoto KM. Idiopathic thrombocytopenic purpura. Pediatr Rev. 2000;21(3):95–104
  21. Langholz B, Goldstein L. Risk set sampling in epidemiologic cohort studies. Stat Sci. 1996;11:35–53
  22. Greenland S. Estimation of exposure-specific rates from sparse case-control data. J Chronic Dis. 1987;40(12):1087–1094
  23. Hosmer DM, Lemethow S. Interpretation of the coefficients of the logistic regression model. In:  Hosmer DM,  Lemeshow S editor. Applied logistic regression. 2nd ed.. New York: John Wiley and Sons, Inc; 2000;p. 8–81
  24. Kleinbaum DG, Kupper LL, Muller KE, et al. Confounding and interaction in regression. In:  Kleinbaum DG,  Kupper LL,  Muller KE, et al. editor. Applied regression analysis and other multivariable methods. 3rd ed.. Pacific Grove, CA: Duxbury; 1998;p. 186–211
  25. Pang D. A relative power table for nested matched case-control studies. Occup Environ Med. 1999;56:67–69
  26. Cologne JB, Sharp GB, Neriishi K, et al. Improving the efficiency of nested case–control studies of interaction by selecting controls using counter matching on exposure. Int J Epidemiol. 2004;33(3):485–492
  27. Schneeweiss S, Sturmer T, Maclure M. Case–crossover and case–time–control designs as alternatives in Phamacoepidemiologic research. Pharmacoepidemiology and Drug Safety. 1997;3:S51–S59
  28. Virtanen M, Peltola H, Paunio M, et al. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics. 2000;106(5):e62
  29. France EK, Glanz JM, Xu S, et al. Safety of the inactivated influenza vaccine among children: A population based study. Arch Pediatr Adolesc Med. 2004;158(11):1031–1035
  30. King G, Zeng L. Logistic regression in rare events data. Soc Politic Methodol. 2001;12(54):137–163

PII: S0895-4356(05)00409-9

doi: 10.1016/j.jclinepi.2005.11.012

Journal of Clinical Epidemiology
Volume 59, Issue 8 , Pages 808-818 , August 2006

Article Tools

* Image Usage & Resolution